Table 1 Overview of inclusion and exclusion criteria

Age > 18 years

Able to give informed consent

One of the following criteria:

 Patients naive for P2Y₁₂ inhibition undergoing ad-hoc PCI

 Patients with STEMI/NSTEMI loaded with oral P2Y₁₂ inhibitors though platelet inhibition still insufficient (< 2 h after oral loading dose) according to operator

 Patients with STEMI/NSTEMI who vomited after P2Y₁₂ loading dose

 Patients with OHCA, based on VF/VT due to acute ischemia as the underlying cause, with Return of Spontaneous Circulation (ROSC) who have successfully been defibrillated and/or resuscitated with stable hemodynamics

 STEMI/NSTEMI patients loaded with oral P2Y₁₂ inhibitors with large thrombus burden (TBG 4 or 5) on initial coronary angiography and undergoing (primary) PCI with expected insufficient P2Y₁₂ inhibition

Patients on current/chronic treatment with P2Y₁₂ inhibitors

Patients (pre)treated with GPIs

Patients with recent major bleeding complications or contraindication to DAPT:

 Hypersensitivity or allergy to and known contraindication to aspirin, clopidogrel, ticagrelor, prasugrel, or cangrelor

 History of major clinical bleeding or known coagulopathy

 Active bleeding

 History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke

 Known severe liver dysfunction

Patients that have received any organ transplant or await any organ transplant

Patients undergoing dialysis

Pregnant or lactating female

Patients currently participating in another investigational drug or drug-coated device study